ArticleActa neurologica Belgica2025
Prevalence of COVID-19 in patients with parkinson's disease and the impact of parkinson's disease on COVID-19 prognosis.
Article in Acta neurologica Belgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to retrospectively evaluate the prevalence of COVID-19 infection among patients with Parkinson's disease (PD), along with the clinical course and factors associated with mortality.
methodsA total of 1,786 patients diagnosed with Parkinson's disease and registered at our hospital were screened. Among these, 222 had undergone PCR testing for COVID-19, of whom 76 tested negative and 152 tested positive, indicating a COVID-19 prevalence of 8.51% in the PD population. Due to insufficient data, 63 of the COVID-19 positive patients were excluded. The final study cohort included 177 patients: 89 patients with PD (50.3%) and 88 age- and sex-matched controls (49.7%). Clinical, laboratory, and prognostic parameters were compared between groups.
resultsThe prevalence of dementia was significantly higher in the PD group. Mortality at both 28 and 90 days was also significantly increased among patients with PD. Notably, those receiving combined therapy with dopamine agonists and levodopa had lower mortality rates at both time points. In patients who died within 28 or 90 days, levels of age, neutrophil count, lymphocyte count, D-dimer, ferritin, C-reactive protein (CRP), and troponin differed significantly compared to survivors.
conclusionPatients with Parkinson's disease represent a vulnerable population at increased risk for adverse outcomes from COVID-19. Close clinical monitoring, continuous dopaminergic treatment, and a personalized approach are essential for optimizing management during COVID-19 infection.
Indexed as
Identifiers
40921993What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.